medigraphic.com

2000, Number 6

<< Back Next >>

Cir Cir 2000; 68 (6)

Is mammaplasty a risk factor in breast cancer?

Hernández-Sánchez RV

Language: Spanish
References: 29
Page: 240-246
PDF size: 96.36 Kb.


ABSTRACT

With the purpose of knowing whether reduction mamoplasty could be a risk factor in breast cancer; which is considered the antecedent of breast biopsy, accepted as risk factor for breast cancer, the cases of breast cancer related to reductin mammoplasty were investigated in 950 women with breast cancer stages I y II treated with modified radical mastectomy and conservative surgery, accumulated over a period of 20 years. We found 16 women with association of breast reduction and cancer. From this study, we can say that it is not the volume of mammarian tissue excised that determines the risk an but the conditions of the glandular, ductal, or lobular tissue no at no the time of biopsy or reduction surgery, which determines the future risk of developing mammarian cancer. Women with ductal or lobular tissue in biopsy or reduction tissue have increase in risk for breast cancer. A group of 10 females with breast reduction with normal mammary tissue followed for 10 years or more no have not presented breast cancer. When there are fibrocystic conditions we observed no increase in the risk of breast cancer. If there are macrocysts the risk of breast cancer is increased. In the case of atypical hyperplasia the risk is four times. The presence of other risk factors, such as familiar breast cancer, first pregnancy after. 30 years of age, large breagts are joined together and increase the risk for atypical hyperplasia. It is imperative to study pathologically tissue excised in biopsy or reduction surgery. The volume of breast tissue excised is not the determinant factor in cancer risk it is, rathen, the material and changes in the epithelium the determinants in the risk of breast cancer are found. This study reinforces the concept that breast cancer is a disease that has a slow an long evolution.


REFERENCES

  1. Warren S. The relation of “chronic mastitis” to carcinoma of the breast. Surg Gynecol Obstet 1940; 71: 257-273.

  2. Dupont WD, Page DL. Risk factors for breast cancer with proliferative breast disease. N Engl J Med 1985; 312: 146-151.

  3. Dupont WD, Page DL. Breast cancer risk associated with proliferative disease, age of first birth, and a family history of breast cancer. Am J Epidemiol 1987; 125: 769-779.

  4. Dupont WD, Page DL. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. Hum Pathol 1989; 20: 723-725.

  5. Cutler SJ, Young JL Jr, Editors Third National Cancer Survey: Incidence data. Bethesda, MD, USA: National Cancer Institute; (DHEW no. (NIH) 1975; 230: 74-787.

  6. MacMahon B, Cole P, Lin TM, Lower CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S. Age at first birth and breast cancer risk. Bull Who 1970; 43. 209-221.

  7. Page DL, Anderson TJ, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast: a long-term follow up study. Cancer 1985; 52: 2698-2708.

  8. Morrow M, Harris JR, Schmitt SJ. Local control following breast conserving surgery for invasive cancer: results of clinical trials. J Natl Cancer Inst 1995; 87: 1669-73.

  9. Di Marino I, Murenu G, Demontis B, Licheri S. Reconstructive surgery in operable breast cancer. Critical evaluation. Ann NY Acad Sci 1993; 698: 227-45.

  10. Lindsey I, Serpell JW, Johnson WR, Rodger A. Cosmesis following complete local excision of breast cancer. Aust NZJ Surgery 1997; 67: 428-32.

  11. Jansen DA, Murphy M, Kind GM, Sands K. Breast cancer in reduction mammoplasty: case reports and survey of plastic surgeons. Plastic Reconstr Surg 1998; 101: 361-4.

  12. Klamer TW, Donegan WL, Max MH. Breast tumor incidence in rats after partial mammary resection. Surgery 1983; 118: 933-938.

  13. Wong JH, I. Analysis of the risk reduction of prophylactic partial mastectomy in Sprague-Dawley rats with 7, 12 dimethyl benzaantracen-induced breast cancer. Surgery 1986, 99: 67-71.

  14. Slavin SA, Schnitt SJ, Duda RB. Skin sparing mastectomy and immediate reconstruction: oncologic risks and aesthetic results in patients with early stage breast cancer. Plast Reconstr Surg 1998; 102: 49-62.

  15. Horton CE, Doscombe WH. Total mastectomy: indications and techniques. Clin Plast Surg 1988; 15: 677-706.

  16. Bellamy CO, McDonald C, Salter DM et al. Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization. Hum Pathol 1993; 24: 16-23.

  17. Douglas-Jones AG, Gupta SK, Attanoos RL et al. A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS) correlation with grade of associated invasive carcinoma. Histopathology 1996; 29: 397-409.

  18. Franceschi S. Breast size, breast reduction, and cancer risk (editorial, comment) Cancer Cause Control (Engl) 1997; 8: 125-6.

  19. Natarajan N, Nemoto T, Mettlin C et al. Race-related differences in breast cancer patients: results of the 1982 National Survey of Breast Cancer by the American College of Surgeons. Cancer 1985; 56: 1704-1709.

  20. Winchester PD, Jeske MJ, Goldschmidt AR. The diagnosis and management of ductal carcinoma in situ of the breast. CA Cancer J Clin 2000; 50: 184-2000.

  21. Haagensen CD, Lane N, Lattes R, Bodian C. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978; 42: 737-769.

  22. Winchestr PD, Strom EA. Standards for diagnosis and management of ductal carcinoma in situ (DCIS) of the breast. CA Cancer J Clin 1998; 48: 108-128.

  23. Singletary SE. Sking-sparing mastectomy with immediate breast reconstruction: The MD. Anderson Cancer Center experience. Ann Surg Oncol 1966; 3: 411-416.

  24. Crowe JP Jr. An update on breast cancer. Evolving treatments and persistent questions. Cleve Clin J Med 1996; 63: 48-56.

  25. Reynolds C, Montone KT, Powell CM, Tomaszewski, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997; 138: 5555-60.

  26. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999; 140: 5447-50.

  27. McDivitt RW, Stewart FW. Breast carcinoma in children. JAMA; 1966; 195: 388-390.

  28. Botta G, Fessia L, Ghiringhello B. Juvenile milk protein secretoring carcinoma. Virchows Arch Pathol Anat 1982; 395: 145-152.

  29. Guerry P, Erlandson RA, Rosen PP. Cystic hypersecretory hyperplasia and cystic hupersecretory duct carcinoma of the breast. Pathology, therapy and follow-up of 39 patients. Cancer 1988; 61: 1611-1620.




2020     |     www.medigraphic.com